Atypical Parkinsonian Syndromes: Structural, Functional, and Molecular Imaging Features

References

1. 1.↵
   1. Goldman JG,
   2. Goetz CG,
   3. Brandabur M, et al

   . Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008;23:2248–50 doi:10.1002/mds.22322 pmid:18823039

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Dugger BN,
   2. Adler CH,
   3. Shill HA, et al

   ; Arizona Parkinson’s Disease Consortium. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord 2014;20:525–29 doi:10.1016/j.parkreldis.2014.02.012 pmid:24637124

   CrossRefPubMed
3. 3.↵
   1. Dugger BN,
   2. Dickson DW

   . Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 2017;9:a028035 doi:10.1101/cshperspect.a028035 pmid:28062563

   Abstract/FREE Full Text
4. 4.↵
   1. Irwin DJ,
   2. Hurtig HI

   . The contribution of tau, amyloid-beta and alpha-synuclein pathology to dementia in Lewy body disorders. J Alzheimer’s Dis Park 2018;8:444
5. 5.↵
   1. McKeith IG,
   2. Boeve BF,
   3. Dickson DW, et al

   . Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 2017;89:88–100 doi:10.1212/WNL.0000000000004058 pmid:28592453

   CrossRefPubMed
6. 6.↵
   1. Broski SM,
   2. Hunt CH,
   3. Johnson GB, et al

   . Structural and functional imaging in parkinsonian syndromes. Radiographics 2014;34:1273–92 doi:10.1148/rg.345140009 pmid:25208280

   CrossRefPubMed
7. 7.↵
   1. Koedam EL,
   2. Lehmann M,
   3. van der Flier WM, et al

   . Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiology 2011;21:2618–25 doi:10.1007/s00330-011-2205-4 pmid:21805370

   CrossRefPubMed
8. 8.↵
   1. Oppedal K,
   2. Ferreira D,
   3. Cavallin L, et al

   ; Alzheimer's Disease Neuroimaging Initiative. A signature pattern of cortical atrophy in dementia with Lewy bodies: a study on 333 patients from the European DLB consortium. Alzheimers Dement 2019;15:400–09 doi:10.1016/j.jalz.2018.09.011 pmid:30439333

   CrossRefPubMed
9. 9.↵
   1. Nakatsuka T,
   2. Imabayashi E,
   3. Matsuda H, et al

   . Discrimination of dementia with Lewy bodies from Alzheimer’s disease using voxel-based morphometry of white matter by statistical parametric mapping 8 plus diffeomorphic anatomic registration through exponentiated lie algebra. Neuroradiology 2013;55:559–66 doi:10.1007/s00234-013-1138-9 pmid:23322456

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Schumacher J,
    2. Peraza LR,
    3. Firbank M, et al

    . Functional connectivity in dementia with Lewy bodies: a within- and between-network analysis. Hum Brain Mapp 2018;39:1118–29 doi:10.1002/hbm.23901 pmid:29193464

    CrossRefPubMed
11. 11.↵
    1. Watson R,
    2. Blamire AM,
    3. Colloby SJ, et al

    . Characterizing dementia with Lewy bodies by means of diffusion tensor imaging. Neurology 2012;79:906–14 doi:10.1212/WNL.0b013e318266fc51 pmid:22895591

    Abstract/FREE Full Text
12. 12.↵
    1. Roquet D,
    2. Sourty M,
    3. Botzung A, et al

    . Brain perfusion in dementia with Lewy bodies and Alzheimer’s disease: an arterial spin labeling MRI study on prodromal and mild dementia stages. Alzheimer’s Res Ther 2016;8:1–13

    CrossRefPubMed
13. 13.↵
    1. Whitwell JL,
    2. Graff-Radford J,
    3. Singh TD, et al

    . ¹⁸F-FDG PET in posterior cortical atrophy and dementia with Lewy bodies. J Nucl Med 2017;58:632–38 doi:10.2967/jnumed.116.179903 pmid:27688479

    Abstract/FREE Full Text
14. 14.↵
    1. Iizuka T,
    2. Iizuka R,
    3. Kameyama M

    . Cingulate island sign temporally changes in dementia with Lewy bodies. Sci Rep 2017;7:14745 doi:10.1038/s41598-017-15263-2 pmid:29116145

    CrossRefPubMed
15. 15.↵
    1. Caminiti SP,
    2. Sala A,
    3. Iaccarino L, et al

    . Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. Alzheimer’s Res Ther 2019;11:1–14

    CrossRefPubMed
16. 16.↵
    1. Rowe CC,
    2. Villemagne VL

    . Brain amyloid imaging. J Nucl Med Technol 2013;41:11–18 doi:10.2967/jnumed.110.076315 pmid:23396994

    Abstract/FREE Full Text
17. 17.↵
    1. Kantarci K,
    2. Lowe VJ,
    3. Chen Q, et al

    . β-amyloid PET and neuropathology in dementia with Lewy bodies. Neurology 2020;94:e282–91 doi:10.1212/WNL.0000000000008818 pmid:31862783

    Abstract/FREE Full Text
18. 18.↵
    1. Walker RWH,
    2. Walker Z

    . Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. Mov Disord 2009;24 Suppl 2:S754–59 doi:10.1002/mds.22591 pmid:19877236

    CrossRefPubMed
19. 19.↵
    1. Chung SJ,
    2. Lee YH,
    3. Yoo HS, et al

    . Distinct FP-CIT PET patterns of Alzheimer’s disease with parkinsonism and dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 2019;46:1652–60 doi:10.1007/s00259-019-04315-6 pmid:30980099

    CrossRefPubMed
20. 20.↵
    1. Khamis K,
    2. Giladi N,
    3. Levine C, et al

    . The added value of ¹⁸F-FDOPA PET/CT in the work-up of patients with movement disorders. Neurograph 2019;9:344–48 doi:10.3174/ng.1900004

    CrossRef
21. 21.↵
    1. Walker Z,
    2. Costa DC,
    3. Janssen AG, et al

    . Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997;24:609–14 doi:10.1007/BF00841397 pmid:9169566

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Slaets S,
    2. Van Acker F,
    3. Versijpt J, et al

    . Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. Int J Geriatr Psychiatry 2015;30:864–69 doi:10.1002/gps.4229 pmid:25363642

    CrossRefPubMed
23. 23.↵
    1. Höglinger GU,
    2. Respondek G,
    3. Stamelou M, et al

    ; Movement Disorder Society-Endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 2017;32:853–64 doi:10.1002/mds.26987 pmid:28467028

    CrossRefPubMed
24. 24.↵
    1. Hauw JJ,
    2. Daniel SE,
    3. Dickson D, et al

    . Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015–19 doi:10.1212/wnl.44.11.2015 pmid:7969952

    Abstract/FREE Full Text
25. 25.↵
    1. Kataoka H,
    2. Tonomura Y,
    3. Taoka T, et al

    . Signal changes of superior cerebellar peduncle on fluid-attenuated inversion recovery in progressive supranuclear palsy. Parkinsonism Relat Disord 2008;14:63–65 doi:10.1016/j.parkreldis.2007.03.001 pmid:17481936

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Paviour DC,
    2. Price SL,
    3. Stevens JM, et al

    . Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2005;64:675–79 doi:10.1212/01.WNL.0000151854.85743.C7 pmid:15728291

    Abstract/FREE Full Text
27. 27.↵
    1. Righini A,
    2. Antonini A,
    3. De Notaris R, et al

    . MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. AJNR Am J Neuroradiol 2004;25:927–32

    PubMedWeb of Science
28. 28.↵
    1. Massey LA,
    2. Micallef C,
    3. Paviour DC, et al

    . Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012;27:1754–62 doi:10.1002/mds.24968 pmid:22488922

    CrossRefPubMed
29. 29.↵
    1. Whitwell JL,
    2. Schwarz CG,
    3. Reid RI, et al

    . Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord 2014;20:493–98 doi:10.1016/j.parkreldis.2014.01.023 pmid:24656943

    CrossRefPubMed
30. 30.↵
    1. Bharti K,
    2. Bologna M,
    3. Upadhyay N, et al

    . Abnormal resting-state functional connectivity in progressive supranuclear palsy and corticobasal syndrome. Front Neurol 2017;8:248 doi:10.3389/fneur.2017.00248 pmid:28634465

    CrossRefPubMed
31. 31.↵
    1. Zhao P,
    2. Zhang B,
    3. Gao S

    . 18F-FDG PET study on the idiopathic Parkinson’s disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord 2012;18 Suppl 1:S60–62 doi:10.1016/S1353-8020(11)70020-7 pmid:22166456

    CrossRefPubMed
32. 32.↵
    1. Tripathi M,
    2. Dhawan V,
    3. Peng S, et al

    . Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology 2013;55:483–92 doi:10.1007/s00234-012-1132-7 pmid:23314836

    CrossRefPubMed
33. 33.↵
    1. Niccolini F,
    2. Politis M

    . A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. Eur J Nucl Med Mol Imaging 2016;43:2244–54 doi:10.1007/s00259-016-3464-8 pmid:27470326

    CrossRefPubMed
34. 34.↵
    1. Eckert T,
    2. Barnes A,
    3. Dhawan V, et al

    . FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912–21 doi:10.1016/j.neuroimage.2005.03.012 pmid:15955501

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Yoo HS,
    2. Chung SJ,
    3. Kim SJ, et al

    . The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage. Eur J Nucl Med Mol Imaging 2018;45:1585–95 doi:10.1007/s00259-018-4019-y pmid:29728749

    CrossRefPubMed
36. 36.↵
    1. Whitwell JL,
    2. Tosakulwong N,
    3. Botha H, et al

    . Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage Clin 2020;25:102152

    CrossRefPubMed
37. 37.↵
    1. Brendel M,
    2. Barthel H,
    3. van Eimeren T, et al

    . Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol 2020;77:1408–19 doi:10.1001/jamaneurol.2020.2526 pmid:33165511

    CrossRefPubMed
38. 38.↵
    1. Aguero C,
    2. Dhaynaut M,
    3. Normandin MD, et al

    . Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun 2019;7:37 doi:10.1186/s40478-019-0686-6 pmid:30857558

    CrossRefPubMed
39. 39.↵
    1. Wenning GK,
    2. Stankovic I,
    3. Vignatelli L, et al

    . The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord 2022;37:1131–48 doi:10.1002/mds.29005 pmid:35445419

    CrossRefPubMed
40. 40.↵
    1. Lee WH,
    2. Lee CC,
    3. Shyu WC, et al

    . Hyperintense putaminal rim sign is not a hallmark of multiple system atrophy at 3T. AJNR Am J Neuroradiol 2005;26:2238–42 pmid:16219828

    PubMed
41. 41.↵
    1. Franceschi AM,
    2. Franceschi D

    1. Zamora C,
    2. Muhleman M,
    3. Castillo M

    . Multiple system atrophy. In: Franceschi AM, Franceschi D, eds. Hybrid PET/MR Neuroimaging: A Comprehensive Approach. Springer-Verlag; 2022:361–82
42. 42.↵
    1. Aquino D,
    2. Bizzi A,
    3. Grisoli M, et al

    . Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology 2009;252:165–72 doi:10.1148/radiol.2522081399 pmid:19561255

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Tha KK,
    2. Terae S,
    3. Tsukahara A, et al

    . Hyperintense putaminal rim at 1. 5 T: prevalence in normal subjects and distinguishing features from multiple system atrophy. BMC Neurol 2012;12:39 doi:10.1186/1471-2377-12-39 pmid:22708511

    CrossRefPubMed
44. 44.↵
    1. Mascalchi M,
    2. Vella A,
    3. Ceravolo R

    . Movement disorders: role of imaging in diagnosis. J Magn Reson Imaging 2012;35:239–56 doi:10.1002/jmri.22825 pmid:22271273

    CrossRefPubMed
45. 45.↵
    1. Brooks DJ,
    2. Seppi K

    ; Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009;24:949–64 doi:10.1002/mds.22413 pmid:19306362

    CrossRefPubMed
46. 46.↵
    1. Lee YC,
    2. Liu CS,
    3. Wu HM, et al

    . The ‘hot cross bun’ sign in the patients with spinocerebellar ataxia. Eur J Neurol 2009;16:513–16 doi:10.1111/j.1468-1331.2008.02524.x pmid:19187260

    CrossRefPubMed
47. 47.↵
    1. Bhattacharya K,
    2. Saadia D,
    3. Eisenkraft B, et al

    . Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002;59:835–42 doi:10.1001/archneur.59.5.835 pmid:12020268

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Cicilet S,
    2. Furruqh F,
    3. Biswas A, et al

    . Hot cross bun and bright middle cerebellar peduncle signs in cerebellar type multiple system atrophy. BMJ Case Rep 2017:bcr-2017-220576 doi:10.1136/bcr-2017-220576

    FREE Full Text
49. 49.↵
    1. Chandran V,
    2. Stoessl AJ

    . Imaging in multiple system atrophy. Neurology & Clinical Neurosc 2014;2:178–87 doi:10.1111/ncn3.125

    CrossRef
50. 50.↵
    1. Kim H-J,
    2. Jeon B,
    3. Fung VSC

    . Role of magnetic resonance imaging in the diagnosis of multiple system atrophy. Mov Disord Clin Pract 2016;4:12–20 doi:10.1002/mdc3.12404 pmid:30363358

    CrossRefPubMed
51. 51.↵
    1. Shiga K,
    2. Yamada K,
    3. Yoshikawa K, et al

    . Local tissue anisotropy decreases in cerebellopetal fibers and pyramidal tract in multiple system atrophy. J Neurol 2005;252:589–96 doi:10.1007/s00415-005-0708-0 pmid:15834652

    CrossRefPubMedWeb of Science
52. 52.↵
    1. Oishi K,
    2. Konishi J,
    3. Mori S, et al

    . Reduced fractional anisotropy in early-stage cerebellar variant of multiple system atrophy. J Neuroimaging 2009;19:127–31 doi:10.1111/j.1552-6569.2008.00262.x pmid:18498329

    CrossRefPubMed
53. 53.↵
    1. Filippi M,
    2. Sarasso E,
    3. Agosta F

    . Resting-state functional MRI in parkinsonian syndromes. Mov Disord Clin Pract 2019;6:104–17 doi:10.1002/mdc3.12730 pmid:30838308

    CrossRefPubMed
54. 54.↵
    1. Zheng W,
    2. Ren S,
    3. Zhang H, et al

    . Spatial patterns of decreased cerebral blood flow and functional connectivity in multiple system atrophy (cerebellar-type): a combined arterial spin labeling perfusion and resting state functional magnetic resonance imaging study. Front Neurosci 2019;13:777 doi:10.3389/fnins.2019.00777 pmid:31417345

    CrossRefPubMed
55. 55.↵
    1. Meyer PT,
    2. Frings L,
    3. Rücker G, et al

    . ¹⁸F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 2017;58:1888–98 doi:10.2967/jnumed.116.186403 pmid:28912150

    Abstract/FREE Full Text
56. 56.↵
    1. Hong C-M,
    2. Ryu H-S,
    3. Ahn B-C

    . Early perfusion and dopamine transporter imaging using ¹⁸F-FP-CIT PET/CT in patients with parkinsonism. Am J Nucl Med Mol Imaging 2018;8:360–72 pmid:30697456

    PubMed
57. 57.↵
    1. Oh M,
    2. Lee N,
    3. Kim C, et al

    . Diagnostic accuracy of dual-phase ¹⁸F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism. Sci Rep 2021;11:14992 doi:10.1038/s41598-021-94040-8 pmid:34294739

    CrossRefPubMed
58. 58.↵
    1. Van Laere K,
    2. Clerinx K,
    3. D’Hondt E, et al

    . Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med 2010;51:588–95 doi:10.2967/jnumed.109.070144 pmid:20237023

    Abstract/FREE Full Text
59. 59.↵
    1. Cho H,
    2. Choi JY,
    3. Lee SH, et al

    . ¹⁸F-AV-1451 binds to putamen in multiple system atrophy. Mov Disord 2017;32:171–73 doi:10.1002/mds.26857 pmid:27859717

    CrossRefPubMed
60. 60.↵
    1. Franceschi AM,
    2. Franceschi D

    1. Niethammer M

    . Corticobasal degeneration. In: Franceschi AM, Franceschi D, eds. Hybrid PET/MR Neuroimaging: A Comprehensive Approach. Springer-Verlag; 2022:373–86
61. 61.↵
    1. Mahapatra RK,
    2. Edwards MJ,
    3. Schott JM, et al

    . Corticobasal degeneration. Lancet Neurol 2004;3:736–43 doi:10.1016/S1474-4422(04)00936-6 pmid:15556806

    CrossRefPubMedWeb of Science
62. 62.↵
    1. Boeve BF

    . The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study. J Mol Neurosci 2011;45:350–53 doi:10.1007/s12031-011-9624-1 pmid:21853287

    CrossRefPubMed
63. 63.↵
    1. Armstrong MJ,
    2. Litvan I,
    3. Lang AE, et al

    . Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496–503 doi:10.1212/WNL.0b013e31827f0fd1 pmid:23359374

    Abstract/FREE Full Text
64. 64.↵
    1. Seritan AL,
    2. Mendez MF,
    3. Silverman DHS, et al

    . Functional imaging as a window to dementia: corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2004;16:393–99 doi:10.1176/jnp.16.4.393 pmid:15616165

    CrossRefPubMed
65. 65.↵
    1. Abe K,
    2. Terakawa H,
    3. Takanashi M, et al

    . Proton magnetic resonance spectroscopy of patients with parkinsonism. Brain Res Bull 2000;52:589–95 doi:10.1016/s0361-9230(00)00321-x pmid:10974501

    CrossRefPubMedWeb of Science
66. 66.↵
    1. Tedeschi G,
    2. Litvan I,
    3. Bonavita S, et al

    . Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson’s disease and corticobasal degeneration. Brain 1997;120 (Pt 9):1541–52 doi:10.1093/brain/120.9.1541 pmid:9313638

    CrossRefPubMed
67. 67.↵
    1. Yamaguchi T,
    2. Ikawa M,
    3. Enomoto S, et al

    . Arterial spin labeling imaging for the detection of cerebral blood flow asymmetry in patients with corticobasal syndrome. Neuroradiology 2022;64:1829–37 doi:10.1007/s00234-022-02942-9 pmid:35399110

    CrossRefPubMed
68. 68.↵
    1. Blin J,
    2. Vidailhet M,
    3. Pillon B, et al

    . Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 1992;7:348–54 doi:10.1002/mds.870070409 pmid:1484530

    CrossRefPubMedWeb of Science
69. 69.↵
    1. Pardini M,
    2. Huey ED,
    3. Spina S, et al

    . FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology 2019;92:e1121–35 doi:10.1212/WNL.0000000000007038 pmid:30700592

    Abstract/FREE Full Text
70. 70.↵
    1. Cho H,
    2. Baek MS,
    3. Choi JY, et al

    . ¹⁸F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome. Neurology 2017;89:1170–78 doi:10.1212/WNL.0000000000004364 pmid:28814462

    Abstract/FREE Full Text
71. 71.↵
    1. Pirker W,
    2. Djamshidian S,
    3. Asenbaum S, et al

    . Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002;17:45–53 doi:10.1002/mds.1265 pmid:11835438

    CrossRefPubMedWeb of Science
72. 72.↵
    1. Kikuchi A,
    2. Okamura N,
    3. Hasegawa T, et al

    . In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 2016;87:2309–16 doi:10.1212/WNL.0000000000003375 pmid:27794115

    Abstract/FREE Full Text
73. 73.↵
    1. Palleis C,
    2. Brendel M,
    3. Finze A, et al

    ; German Imaging Initiative for Tauopathies (GII4T). Cortical [¹⁸F]PI-2620 binding differentiates corticobasal syndrome subtypes. Mov Disord 2021;36:2104–15 doi:10.1002/mds.28624 pmid:33951244

    CrossRefPubMed
74. 74.↵
    1. Tezuka T,
    2. Takahata K,
    3. Seki M, et al

    . Evaluation of [18 F] PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun 2021;3:1–13
75. 75.↵
    1. Wardlaw JM,
    2. Smith EE,
    3. Biessels GJ, et al

    ; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–38 doi:10.1016/S1474-4422(13)70124-8 pmid:23867200

    CrossRefPubMedWeb of Science
76. 76.↵
    1. Vizcarra JA,
    2. Lang AE,
    3. Sethi KD, et al

    . Vascular parkinsonism: deconstructing a syndrome. Mov Disord 2015;30:886–94 doi:10.1002/mds.26263 pmid:25997420

    CrossRefPubMed
77. 77.↵
    1. Ma KKY,
    2. Lin S,
    3. Mok VCT

    . Neuroimaging in vascular parkinsonism. Curr Neurol Neurosci Rep 2019;19:102 doi:10.1007/s11910-019-1019-7 pmid:31773419

    CrossRefPubMed
78. 78.↵
    1. Antonini A,
    2. Vitale C,
    3. Barone P, et al

    . The relationship between cerebral vascular disease and parkinsonism: the VADO study. Parkinsonism Relat Disord 2012;18:775–80 doi:10.1016/j.parkreldis.2012.03.017 pmid:22531611

    CrossRefPubMedWeb of Science
79. 79.↵
    1. Rissardo JP,
    2. Caprara ALF

    . Cinnarizine- and flunarizine-associated movement disorder: a literature review. Egyp J Neurol Psych Neurosurg 2020;56:61
80. 80.↵
    1. Pitton Rissardo J,
    2. Caprara ALF

    . Neuroimaging techniques in differentiating Parkinson’s disease from drug-induced parkinsonism: a comprehensive review. Clin Pract 2023;13:1427–48 doi:10.3390/clinpract13060128 pmid:37987429

    CrossRefPubMed
81. 81.↵
    1. Laruelle M,
    2. Abi-Dargham A,
    3. van Dyck CH, et al

    . Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996;93:9235–40 doi:10.1073/pnas.93.17.9235 pmid:8799184

    Abstract/FREE Full Text
82. 82.↵
    1. Burn DJ,
    2. Brooks DJ

    . Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology 1993;43:552–56 doi:10.1212/wnl.43.3_part_1.552 pmid:8451000

    Abstract/FREE Full Text